David Oakes
Affiliations: | University of Rochester, Rochester, NY |
Area:
Biostatistics Biology, StatisticsGoogle:
"David Oakes"Children
Sign in to add trainee| Changyong Feng | grad student | 2002 | Rochester |
| Antai Wang | grad student | 2002 | Rochester |
| Xiaomin He | grad student | 2006 | Rochester |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Siderowf A, Jennings D, Stern M, et al. (2020) Clinical and Imaging Progression in the PARS Cohort: Long-Term Follow-up. Movement Disorders : Official Journal of the Movement Disorder Society |
| Anderson KE, Eberly S, Marder KS, et al. (2019) The choice not to undergo genetic testing for Huntington disease: Results from the PHAROS study. Clinical Genetics |
| Mestre TA, Eberly S, Tanner C, et al. (2018) Reply to "Studying reproducibility of data-driven Parkinson's disease subtypes". Parkinsonism & Related Disorders |
| Zareba W, Daubert JP, Beck CA, et al. (2018) Ranolazine in High-Risk Patients With Implanted Cardioverter-Defibrillators: The RAID Trial. Journal of the American College of Cardiology. 72: 636-645 |
| Mestre TA, Eberly S, Tanner C, et al. (2018) Reproducibility of data-driven Parkinson's disease subtypes for clinical research. Parkinsonism & Related Disorders |
| Hersch SM, Schifitto G, Oakes D, et al. (2017) The CREST-E study of creatine for Huntington disease: A randomized controlled trial. Neurology |
| Jennings D, Siderowf A, Stern M, et al. (2017) Conversion to Parkinson Disease in the PARS Hyposmic and Dopamine Transporter-Deficit Prodromal Cohort. Jama Neurology |
| Biglan KM, Oakes D, Lang AE, et al. (2017) A novel design of a Phase III trial of isradipine in early Parkinson disease (STEADY-PD III). Annals of Clinical and Translational Neurology. 4: 360-368 |
| Kurlan R, Ravina B, Eberly S, et al. (2016) Early Clinical Predictors of Treatment-Resistant and Functional Outcomes in Parkinson's Disease. Movement Disorders Clinical Practice. 3: 53-58 |
| Biglan KM, Shoulson I, et al. (2015) Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials. Jama Neurology. 1-9 |